Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Acquisition expands high-value medical platform
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
Lidocaine and Prilocaine cream had annual sales of US $22.05 million in the United States (IQVIA MAT October 2024)
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
Subscribe To Our Newsletter & Stay Updated